a,Schematic diagram showing multiple miRNA response
elements (MRE) for miR-27b, miR-33a, miR-33b and miR-128 in CHROME variants.
b, RNAcofold-predicted changes in Gibbs free energy (ΔG)
upon binding of CHROME variants to miR-27b, miR-33a, miR-33b,
miR-128 or miR-16 (control). c, Enrichment of
CHROME RNA in AGO2-immunoprecipitates from primary human
hepatocytes and THP-1 macrophages relative to IgG control. d, qPCR
detection of miRNAs in CHROME-1, CHROME-3 and
CHROME-7 ribonucleoprotein complexes precipitated using
MS2-tagged RNA affinity purification (MS2-TRAP). Data are normalized to
U6 and control MS2-bs-vector. c-d) Data are
the mean ± SEM of a single experiment and are representative of 3
independent experiments. e, Fluorescence in situ
hybridization for CHROME (red: top) and immunostaining for the
P-body marker EDC4 (red: bottom) in HEK293T cells expressing AGO2-GFP (green)
and stained with DAPI nuclear stain (blue). Arrows in merged image indicate
signal colocalization (yellow) in punctate structures. Staining is
representative of 2 independent experiments. f, Cumulative
distribution plots of log2-transformed gene expression fold changes from RNA-Seq
of CHROME-shRNA vs control-shRNA HepG2 cells (3 biological
replicates each), showing genes containing miR-27b, miR-33a/miR-33b or miR-128
target sites predicted by Targetscan (blue) and all other expressed genes (red).
As a control, similar analyses were performed for genes containing target sites
of miR-122, a hepatic miRNA with known roles in lipid metabolism. The increased
prevalence of negative log2-fold changes among predicted targets of miR-27b,
miR-33 and miR-128 (left shift of blue line compared to red), but not miR-122,
suggests increased inhibitory effects of those miRNAs upon
CHROME knockdown. P-values were calculated a two-sample
Kolmogorov-Smirnov test.